AC
FULC icon

AXQ Capital’s Fulcrum Therapeutics FULC Stock Holding History

AXQ Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
81,483
+59,440
+270% +$362K 0.03% 620
2026
Q1 		$169K Sell
22,043
-9,502
-30% -$88.1K 0.02% 788
2025
Q4 		$357K Buy
+31,545
New +$321K 0.08% 381

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AXQ Capital's FULC Position: Q2 2026 in Review

AXQ Capital increased its Fulcrum Therapeutics (FULC) stake by 270% in Q2 2026, buying an estimated $362K and bringing the position to 81,483 shares worth $298K. The position accounts for 0.03% of the portfolio, ranked #620.

AXQ Capital first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. The position peaked at $357K in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • AXQ Capital held 81,483 shares of Fulcrum Therapeutics worth $298K as of Q2 2026.
  • AXQ Capital bought 59,440 Fulcrum Therapeutics shares in Q2 2026, an estimated $362K.
  • Fulcrum Therapeutics made up 0.03% of AXQ Capital's portfolio in Q2 2026, its #620 holding.
  • AXQ Capital first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • AXQ Capital's Fulcrum Therapeutics position peaked at $357K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.